Hoverman Daniel S. 4/A
4/A · OncBioMune Pharmaceuticals, Inc · Filed Mar 14, 2019
Insider Transaction Report
Form 4/AAmended
Hoverman Daniel S.
Director
Transactions
- Award
Stock Option (right to buy)
2018-05-09+3,000,000→ 3,000,000 totalExercise: $0.01From: 2019-05-09Exp: 2028-05-09→ Common Stock (3,000,000 underlying) - Award
Stock Option (right to buy)
2017-04-17+350,000→ 350,000 totalExercise: $0.27From: 2018-04-17Exp: 2027-04-17→ Common Stock (350,000 underlying)
Footnotes (2)
- [F1]Options issued as compensation approved by the Issuer's Board of Directors.
- [F2]This form is being amended because the original Form 4 aggregated the two grants listed above as the same class of options, when they are actually two separate classes.